Our data on NfL in SMA patients, along with findings of other groups, raise questions about whether low treatment‐naïve NfL concentrations within reference ranges may indicate a missed window of opportunity for SMN modifying interventions. The gene discussed is NEFL; the disease is proximal spinal muscular atrophy.